RNA Interference News and Research

RSS
Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Scientists publish study results of AAV therapy product for treatment of RHO-adRP

Scientists publish study results of AAV therapy product for treatment of RHO-adRP

Scientists pinpoint key gene that controls body segmentation in spiders and insects

Scientists pinpoint key gene that controls body segmentation in spiders and insects

Researchers describe link between poor oocyte development and oxidative stress in obese mice

Researchers describe link between poor oocyte development and oxidative stress in obese mice

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

Researchers use DNA editing tool to reveal mechanisms behind autoimmune diseases

Researchers use DNA editing tool to reveal mechanisms behind autoimmune diseases

Researchers describe strategy used by Oropouche virus to replicate in human cells

Researchers describe strategy used by Oropouche virus to replicate in human cells

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Genes associated with autism interact to modulate variable symptoms of disease

Genes associated with autism interact to modulate variable symptoms of disease

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Researchers identify protein essential for eye lens development and clear vision

Researchers identify protein essential for eye lens development and clear vision

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

New eye drop may be potentially effective in treating seasonal eye allergies

New eye drop may be potentially effective in treating seasonal eye allergies

Sylentis presents clinical study results of new treatment for dry eye syndrome

Sylentis presents clinical study results of new treatment for dry eye syndrome